FDA approved drugs – June 2015

Publication History
Received: 6 September 2015
Accepted: 17 September 2015
Published: 1 October 2015

Citation
Vidhya V. FDA approved drugs – June 2015. Drug Discovery, 2015, 10(26), 250-251
1. Drug Name: Kengreal (cangrelor)
Company: The Medicines Company
Approval Status: Approved by June 2015
Therapeutic Areas: Cardiology/Vascular Diseases

General Information
Kengreal is specifically indicated as an adjunct to percutaneous coronary intervention for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. It is supplied as a sterile white to off-white lyophilized powder for reconstitution into an IV infusion. The recommended dosage is a 30 mcg/kg IV bolus followed immediately by a 4 mcg/kg/min IV infusion. Initiate the bolus infusion prior to PCI.

Mechanism of Action
Kengreal (cangrelor) is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signalling and platelet activation.

Side Effects
The most common adverse effect associated with the use of Kengreal is bleeding.